Core Insights - Halozyme Therapeutics, Inc. will release its fourth quarter and full year 2025 financial and operating results on February 17, 2026, after market close [1] - A conference call will be held on the same day at 1:30 PM PT/4:30 PM ET to discuss these results [1] Company Overview - Halozyme is a biopharmaceutical company focused on improving patient experiences and outcomes through innovative drug delivery solutions [1] - The company is known for its ENHANZE® drug delivery technology, which utilizes the proprietary enzyme rHuPH20 to facilitate subcutaneous delivery of drugs, impacting over one million patients globally [1] - Halozyme has partnered with major pharmaceutical companies such as Roche, Takeda, Pfizer, and others to commercialize its technology across more than 100 markets [1] Technology and Product Development - The company has expanded its drug delivery technology portfolio with Hyperconâ™ and Surf Bio's hyperconcentration technology, which aims to reduce injection volume while maintaining dosage [1] - Hyperconâ™ technology has been licensed to leading biopharmaceutical partners, enhancing the delivery of biologics subcutaneously [1] - Halozyme also develops drug-device combination products using advanced auto-injector technologies to improve patient comfort and adherence [1] Corporate Structure - Halozyme is headquartered in San Diego, California, with additional offices in Ewing, New Jersey; Minnetonka, Minnesota; and Boston, Massachusetts [1]

Core Insights - Halozyme Therapeutics has raised its revenue estimates for 2025 and provided updated financial guidance for 2026, reflecting strong growth in its core ENHANZE business and recent acquisitions [1] Financial Estimates for 2025 - Total revenue is estimated to be between $1,385 million and $1,400 million, representing a year-over-year growth of 36% to 38% [1] - Royalty revenue is projected to be between $865 million and $870 million, with a year-over-year growth of 51% to 52% [1] Financial Guidance for 2026 - Total revenue guidance has been increased to a range of $1,710 million to $1,810 million, indicating a year-over-year growth of 23% to 30% [1] - Royalty revenue guidance has been raised to between $1,130 million and $1,170 million, reflecting a growth of 30% to 35% compared to 2025 [1] - Adjusted EBITDA is expected to be between $1,125 million and $1,205 million [1] - Non-GAAP diluted EPS is projected to be between $7.75 and $8.25 [1] Strategic Acquisitions - The company acquired Surf Bio for an upfront payment of $300 million, with potential milestone payments of up to $100 million, totaling up to $400 million [1] - Surf Bio's hyperconcentration technology aims to enable high concentrations of therapeutics for subcutaneous delivery, enhancing patient experience [1] Business Development and Partnerships - In 2025, Halozyme signed three new ENHANZE collaboration and licensing agreements, along with one new auto-injector commercial licensing agreement and two development agreements [1] - The company anticipates having 15 partner programs in development by the end of 2026, further expanding its drug delivery portfolio [1]

Core Insights - Halozyme Therapeutics, Inc. will present at the 8th Annual Evercore Healthcare Conference on December 2, 2025, at 10:20 am PT / 1:20 pm ET, hosted by Dr. Helen Torley, the president and CEO [1] Company Overview - Halozyme is a biopharmaceutical company focused on innovative solutions to enhance patient experiences and outcomes for both emerging and established therapies [3] - The company is known for its ENHANZE® drug delivery technology, which utilizes the proprietary enzyme rHuPH20 to facilitate subcutaneous delivery of injected drugs, improving convenience and reducing treatment burden [4] - ENHANZE® has impacted over one million patients through ten commercialized products across more than 100 global markets, with partnerships involving major pharmaceutical companies such as Roche, Takeda, and Pfizer [4] Technology Development - Halozyme is developing Hypercon™, a microparticle technology aimed at hyper-concentration of drugs and biologics, which is expected to reduce injection volume while expanding at-home and healthcare provider administration opportunities [5] - The Hypercon™ technology has been licensed to leading biopharmaceutical partners, including Johnson & Johnson and Eli Lilly, enhancing the company's drug delivery capabilities [5] Product Portfolio - The company also develops drug-device combination products using advanced auto-injector technologies to improve patient comfort and adherence, with proprietary products like Hylenex® and XYOSTED® [6] - Halozyme has ongoing development programs in collaboration with Teva Pharmaceuticals and McDermott Laboratories Limited, an affiliate of Viatris Inc. [6] Corporate Information - Halozyme is headquartered in San Diego, California, with additional offices in Ewing, New Jersey; Minnetonka, Minnesota; and Boston, Massachusetts [7]

Core Viewpoint - Halozyme Therapeutics, Inc. has announced the pricing of $650 million in 0% convertible senior notes due 2031 and $650 million in 0.875% convertible senior notes due 2032, with an option for initial purchasers to buy an additional $100 million of each series [1][4]. Summary by Sections Convertible Notes Details - The 2031 Notes are senior, unsecured obligations with no regular interest and no principal accretion, while the 2032 Notes will accrue interest at an annual rate of 0.875% payable semi-annually [2]. - The initial conversion rate for both series is 11.4683 shares per $1,000 principal amount, equating to a conversion price of approximately $87.20 per share, representing a 27.5% premium over the closing price of $68.39 on November 6, 2025 [2]. Use of Proceeds - The company expects to receive net proceeds of approximately $1.274 billion, or $1.47 billion if the option for additional notes is fully exercised, after deducting discounts and expenses [4]. - Approximately $182.7 million of the proceeds will fund capped call transactions, while about $1.020 billion will be used to repurchase existing convertible notes due 2027 and 2028 [4][5]. Capped Call Transactions - Capped call transactions have been established to cover the shares underlying the convertible notes, with a cap price of $136.78 per share, representing a 100% premium over the last reported sale price [3][7]. - These transactions are expected to reduce potential dilution upon conversion of the notes and offset cash payments if the market price exceeds the cap price [7]. Market Impact - The note repurchases may influence the market price of the company's common stock and convertible notes, potentially affecting the conversion price and the number of shares received upon conversion [6][10]. - The company anticipates that hedging activities related to the capped call transactions could also impact the market price of its common stock [8][9]. Company Overview - Halozyme is a biopharmaceutical company focused on innovative drug delivery solutions, particularly through its ENHANZE® technology, which facilitates subcutaneous delivery of drugs [14][15]. - The company has partnered with major pharmaceutical firms and has a presence in over 100 global markets, impacting approximately one million patients [14].

Core Insights - Halozyme Therapeutics, Inc. will release its third quarter 2025 financial and operating results on November 3, 2025, after market close [1] - A conference call to discuss the results will be held on the same day at 1:30 p.m. PT/4:30 p.m. ET, accessible via pre-registration [2] Company Overview - Halozyme is a biopharmaceutical company focused on innovative solutions to enhance patient experiences and outcomes, particularly through its ENHANZE® drug delivery technology [3] - The company has impacted over one million patients through its technology, which is licensed to major pharmaceutical companies including Roche, Takeda, and Pfizer [3] - Halozyme also develops drug-device combination products aimed at improving convenience and patient adherence, with two proprietary products, Hylenex® and XYOSTED®, currently on the market [4] Recent Developments - Halozyme has announced a definitive agreement to acquire Elektrofi, Inc., which is expected to enhance its innovative drug delivery offerings and support long-term growth [8]

Core Insights - Halozyme Therapeutics announced the European Commission approval for DARZALEX Faspro® (daratumumab) co-formulated with ENHANZE® for treating high-risk smouldering multiple myeloma (SMM) [1][2] - This approval marks a significant advancement in early intervention strategies for multiple myeloma, addressing critical patient needs [2] Company Overview - Halozyme is a biopharmaceutical company focused on innovative solutions to enhance patient experiences and outcomes, particularly through its ENHANZE® drug delivery technology [4] - The company has successfully licensed its ENHANZE® technology to major pharmaceutical firms, including Roche, Takeda, and Pfizer, among others [4] - Halozyme has two proprietary commercial products, Hylenex® and XYOSTED®, and is involved in ongoing product development with various partners [5] Clinical Study Insights - The EC approval is based on data from the Phase 3 AQUILA study, which compared the efficacy and safety of daratumumab SC monotherapy against active monitoring in high-risk SMM patients [3]

Core Insights - Halozyme Therapeutics, Inc. will release its second quarter 2025 financial and operating results on August 5, 2025, after market close [1] - A conference call to discuss the results will take place on the same day at 1:30 p.m. PT/4:30 p.m. ET, accessible via pre-registration [1] - A live webcast and replay of the conference call will be available on Halozyme's corporate website [2] Company Overview - Halozyme is a biopharmaceutical company focused on innovative solutions to enhance patient experiences and outcomes through its ENHANZE® drug delivery technology [3] - The proprietary enzyme rHuPH20 facilitates subcutaneous delivery of drugs, improving patient experience by enabling rapid delivery and reducing treatment burden [3] - The technology has been utilized in over one million patient lives across ten commercialized products in more than 100 global markets, licensed to major pharmaceutical companies including Roche, Takeda, and Pfizer [3] - Halozyme also develops drug-device combination products using advanced auto-injector technologies, aimed at improving convenience, reliability, and patient adherence [4] - The company has two proprietary commercial products, Hylenex® and XYOSTED®, along with partnerships for product development with Teva Pharmaceuticals and McDermott Laboratories [4] - Halozyme is headquartered in San Diego, CA, with additional offices in Ewing, NJ, and Minnetonka, MN, which also houses its operations facility [5]

Group 1 - Halozyme Therapeutics, Inc. has been added to the U.S. large-cap Russell 1000® Index, effective after market close on June 27, 2025, as part of the 2025 FTSE Russell indexes annual reconstitution [1][2] - The Russell 1000® Index includes approximately 1,000 of the largest U.S. securities based on market capitalization and serves as a benchmark for large-cap stock performance [1][2] - Dr. Helen Torley, President and CEO of Halozyme, stated that joining the Russell 1000 Index reflects the company's leadership in rapid large-volume subcutaneous drug delivery and its track record of durable growth [2] Group 2 - Halozyme is a biopharmaceutical company focused on improving patient experiences and outcomes through its ENHANZE® drug delivery technology, which facilitates subcutaneous delivery of injected drugs [3] - The company has licensed its ENHANZE® technology to major pharmaceutical companies, including Roche, Takeda, and Pfizer, impacting over one million patients globally [3][4] - Halozyme develops drug-device combination products using advanced auto-injector technologies aimed at enhancing patient comfort and adherence [4] Group 3 - The company is headquartered in San Diego, CA, with additional offices in Ewing, NJ, and Minnetonka, MN, where its operations facility is located [5]

Company Overview - Halozyme Therapeutics, Inc. is a biopharmaceutical company focused on improving patient experiences and outcomes through innovative drug delivery solutions [2] - The company is known for its ENHANZE® drug delivery technology, which utilizes the proprietary enzyme rHuPH20 to facilitate subcutaneous delivery of drugs and fluids [2] - Halozyme has impacted over one million patients through its technology, which is used in ten commercialized products across more than 100 global markets [2] Product Development - Halozyme develops, manufactures, and commercializes drug-device combination products, leveraging advanced auto-injector technologies for improved convenience and patient adherence [3] - The company has two proprietary commercial products, Hylenex® and XYOSTED®, and is engaged in partnerships with Teva Pharmaceuticals and McDermott Laboratories Limited [3] Upcoming Events - Dr. Helen Torley, the president and CEO of Halozyme, will participate in investor meetings at the Benchmark 2025 Healthcare House Call Virtual Conference on May 29, 2025 [1] - The company will also be featured at the Goldman Sachs 46th Annual Global Healthcare Conference on June 9, 2025, with a presentation scheduled for 7:00 am PT / 10:00 am ET [1] - Live audio webcasts of the presentations will be available on the company's Investor Relations website, with replays accessible for 90 days post-conference [1]

Company Overview - Halozyme Therapeutics, Inc. is a biopharmaceutical company focused on advancing disruptive solutions to enhance patient experiences and outcomes for both emerging and established therapies [3] - The company is known for its ENHANZE® drug delivery technology, which utilizes the proprietary enzyme rHuPH20 to facilitate subcutaneous delivery of injected drugs and fluids, aiming to improve patient experience through rapid delivery and reduced treatment burden [3] - Halozyme has impacted one million patient lives through post-marketing use of ten commercialized products across more than 100 global markets [3] Product and Technology - Halozyme has licensed its ENHANZE® technology to major pharmaceutical and biotechnology companies, including Roche, Takeda, Pfizer, and AbbVie, among others [3] - The company also develops and commercializes drug-device combination products using advanced auto-injector technologies, which offer advantages such as improved convenience, reliability, and patient comfort [4] - Halozyme has two proprietary commercial products, Hylenex® and XYOSTED®, and is engaged in ongoing product development programs with partners like Teva Pharmaceuticals and McDermott Laboratories Limited [4] Upcoming Events - Dr. Helen Torley, the president and CEO of Halozyme, will present and host investor meetings at the BofA Securities 2025 Healthcare Conference on May 13, 2025, at 4:20 PM PT / 7:20 PM ET [1] - A live audio webcast of the presentation will be available on the company's Investor Relations website, with replays accessible for 90 days post-conference [2]